Cargando…
Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma
BACKGROUND: Multiple myeloma (MM) is a malignant tumor, which takes the second place in malignant blood disease. The clinical symptoms are complicated that make more difficult to diagnose and therapy. Lots of researches focus on the proteins about MM in order to solve those problems. We used proteom...
Autores principales: | Zhang, Hong-Tao, Tian, En-Bing, Chen, Yu-Ling, Deng, Hai-Teng, Wang, Qing-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832954/ https://www.ncbi.nlm.nih.gov/pubmed/25881608 http://dx.doi.org/10.4103/0366-6999.155112 |
Ejemplares similares
-
Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma
por: Apipongrat, Dollapak, et al.
Publicado: (2022) -
Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma
por: Bai, Ju, et al.
Publicado: (2019) -
Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019) -
Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma
por: Zhong, Ling, et al.
Publicado: (2020) -
Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma
por: Chen, Jie, et al.
Publicado: (2015)